MESO Q4 2023 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-3.8% YoY

Gross Profit

-$13M-620.9% margin

Operating Income

-$19M-891.9% margin

Net Income

-$22M-1024.7% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+10.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$669M

Total Liabilities

$168M

Stockholders' Equity

$502M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-3.8%
Gross Profit	-$13M	-$14M	+4.1%
Operating Income	-$19M	-$20M	+3.7%
Net Income	-$22M	-$21M	-2.2%